vTv Therapeutics Inc. (VTVT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

vTv Therapeutics Inc. (VTVT) Healthcare & Pipeline Overview

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical firm specializing in oral therapies for diabetes and inflammatory conditions, distinguishing itself through its liver-selective glucokinase activator (TTP399) and non-CNS penetrant PDE4 inhibitor (HPP737), within the competitive biotechnology sector.

What Is the Investment Thesis for VTVT?

vTv Therapeutics presents a high-risk, high-reward investment profile typical of clinical-stage biopharmaceutical companies. The primary value driver is the successful development and commercialization of TTP399 for type 1 diabetes, a significant unmet medical need. Positive clinical trial results could lead to substantial market capitalization growth. The company's pipeline also offers diversification, with HPP737 targeting inflammatory diseases and psoriasis. However, the company faces significant regulatory and clinical trial risks, as well as competition from established diabetes and inflammation treatments. The company's low market capitalization of $84.8M reflects these risks and the uncertainty surrounding its pipeline. Successful execution of clinical trials and securing regulatory approvals are critical for realizing the company's potential value.

Based on FMP financials and quantitative analysis

VTVT Key Highlights

vTv Therapeutics is focused on orally administered treatments, offering a potential advantage over injectable therapies in patient compliance and convenience.

• The company's lead candidate, TTP399, targets type 1 diabetes, a market with significant unmet needs and potential for high revenue generation.
• vTv Therapeutics has a diversified pipeline with programs targeting inflammatory diseases, cystic fibrosis related diabetes, and renal diseases, reducing reliance on a single product.
• Strategic partnerships with companies like Reneo Pharmaceuticals and Novo Nordisk provide access to resources and expertise, enhancing development capabilities.
• The company's small size (23 employees) allows for agility and focused execution, but also presents challenges in scaling up operations and commercialization.

Who Are VTVT's Competitors?

VTVT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VTVT's Key Strengths?

Novel drug candidates with unique mechanisms of action.

• Oral administration route offers potential patient compliance advantages.
• Strategic partnerships with established pharmaceutical companies.
• Focus on underserved markets with high unmet medical needs.

What Are VTVT's Weaknesses?

Clinical-stage company with no currently marketed products.

• High reliance on successful clinical trial outcomes.
• Limited financial resources compared to larger pharmaceutical companies.
• Small team size may limit operational capacity.

What Could Drive VTVT Stock Higher?

Announcement of Phase 3 clinical trial results for TTP399 in type 1 diabetes.

• Initiation of Phase 2 clinical trials for HPP737 in psoriasis.
• Progress in partnership with Reneo Pharmaceuticals to develop and commercialize HPP593.
• Advancement of Nrf2 activator programs (HPP3033 and HPP971) through preclinical and clinical development.

What Are the Key Risks for VTVT?

Negative return on equity (-6.3%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for key drug candidates.
• Regulatory delays or rejection of marketing applications.
• Competition from established pharmaceutical companies with greater resources.
• Dependence on strategic partnerships for funding and development.
• Intellectual property challenges and patent disputes.

What Are the Growth Opportunities for VTVT?

• Growth opportunity 1: Successful completion of Phase 3 clinical trials for TTP399 in type 1 diabetes could unlock a significant market opportunity. The type 1 diabetes market is estimated to reach $25 billion by 2030, driven by increasing diagnosis rates and demand for innovative therapies. Positive trial results would position TTP399 as a potential first-in-class oral glucokinase activator, offering a competitive advantage over existing insulin therapies. Regulatory approval and commercial launch could generate substantial revenue within 3-5 years.
• Growth opportunity 2: Advancing HPP737 through clinical development for inflammatory diseases, particularly psoriasis, represents another key growth driver. The global psoriasis market is projected to reach $13.5 billion by 2028. HPP737's non-CNS penetrant PDE4 inhibitor mechanism aims to reduce systemic side effects, potentially offering a differentiated profile compared to existing PDE4 inhibitors. Successful clinical trials and regulatory approval could lead to significant market share gains within 5-7 years.
• Growth opportunity 3: Expanding partnerships and licensing agreements to broaden the pipeline and access new technologies. Collaborations with pharmaceutical companies and research institutions can accelerate drug development and reduce financial risk. Licensing new drug candidates or technologies targeting other therapeutic areas, such as oncology or neurology, could diversify the company's portfolio and create new revenue streams. These partnerships can be established within the next 1-2 years.
• Growth opportunity 4: Leveraging the Nrf2 activator programs (HPP3033 and HPP971) to address chronic diseases associated with oxidative stress and renal diseases. The market for Nrf2 activators is growing, driven by increasing understanding of the role of oxidative stress in various chronic conditions. Successful development of these programs could lead to new therapies for diseases such as chronic kidney disease and neurodegenerative disorders, expanding the company's market reach within 5-7 years.
• Growth opportunity 5: Exploring opportunities for azeliragon, a RAGE antagonist, in inflammatory lung diseases and cancers. While previous clinical trials have faced challenges, there may be potential for azeliragon in specific patient populations or in combination with other therapies. Further research and development could unlock new applications for this drug candidate, potentially generating revenue within 5-7 years.

What Are VTVT's Competitive Advantages?

• Proprietary drug candidates with novel mechanisms of action.
• Extensive intellectual property portfolio protecting drug candidates and technologies.
• Strategic partnerships with leading pharmaceutical companies and research institutions.
• Focus on orally administered treatments, offering a potential advantage over injectable therapies.

What Does VTVT Do?

vTv Therapeutics Inc., established in 2015 and headquartered in High Point, North Carolina, is a clinical-stage biopharmaceutical company dedicated to developing orally administered treatments, primarily targeting diabetes and inflammatory diseases. A subsidiary of MacAndrews & Forbes Incorporated, the company's pipeline features several drug candidates, including TTP399, an orally administered, small molecule, and liver-selective glucokinase activator designed for treating type 1 diabetes. Another key asset is HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor aimed at addressing inflammatory diseases and psoriasis. The company is also involved in the clinical development of TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes. Additionally, vTv Therapeutics is exploring HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. vTv Therapeutics has established strategic partnerships and licensing agreements with companies like Reneo Pharmaceuticals, Inc., Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S to advance its research and development efforts.

What Products and Services Does VTVT Offer?

• Develop orally administered treatments for diabetes.
• Develop orally administered treatments for inflammatory diseases.
• Focus on small molecule drug development.
• Target type 1 diabetes with TTP399, a liver-selective glucokinase activator.
• Target inflammatory diseases and psoriasis with HPP737, a non-CNS penetrant PDE4 inhibitor.
• Develop Nrf2 activators for chronic diseases associated with oxidative stress.
• Develop RAGE antagonists for inflammatory lung diseases and cancers.

How Does VTVT Make Money?

• Develop and license pharmaceutical products.
• Conduct clinical trials to demonstrate efficacy and safety of drug candidates.
• Partner with pharmaceutical companies for commercialization.
• Generate revenue through licensing agreements and potential future product sales.

What Industry Does VTVT Operate In?

vTv Therapeutics operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The market for diabetes treatments is substantial and growing, driven by increasing prevalence of both type 1 and type 2 diabetes globally. The inflammatory disease market is also large and diverse, with numerous established and emerging therapies. vTv Therapeutics aims to differentiate itself through its focus on orally administered treatments and novel mechanisms of action. Competition includes major pharmaceutical companies and other biotech firms developing innovative therapies for diabetes and inflammatory conditions.

Who Are VTVT's Key Customers?

• Pharmaceutical companies seeking to license or acquire novel drug candidates.
• Patients with diabetes and inflammatory diseases.
• Healthcare providers prescribing treatments for diabetes and inflammatory diseases.

Over the past six months, vTv Therapeutics Inc. insiders filed 5 SEC Form 4 transactions — 0 sales and 5 purchases. On net that is roughly 30K shares acquired (about $1.1M) — insiders putting money in tends to read as conviction.

vTv Therapeutics Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 63.1% above estimates on average.

vTv Therapeutics Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.99 places it in the grey zone, a middle ground that warrants monitoring.

Return on equity for vTv Therapeutics Inc. stands at -6.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -19.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 12.48 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.2%, the inverse of the P/E and a quick read on earnings relative to price.

vTv Therapeutics Inc. (VTVT) Valuation Context

Valued at $84.8M, VTVT is classified as a micro-cap stock. Analyst price targets span from $42.00 to $42.00, with a consensus of $42.00. At the current price of $32.40, that implies approximately 30% upside potential. Relative to its peer group, VTVT's quantitative score of 37/100 is below the peer average of 79/100.

VTVT Revenue & Earnings Trend

In Q2 FY2026, VTVT generated $0 in top-line revenue, marking a sequential decrease of 100.0%. The company recorded a net loss of $13.1M, with diluted EPS of $-1.05. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, VTVT averaged $-0.03 in diluted EPS.

Company Profile

vTv Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in High Point, US. The company is led by CEO Paul J. Sekhri. VTVT has traded publicly since 2015.

VTVT Financials

VTVT Latest News

VTVT Analyst Consensus

VTVT MoonshotScore

Common Questions About VTVT (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources